Abeona Therapeutics Inc. (ABEO) — SEC Filings
Abeona Therapeutics Inc. (ABEO) — 37 SEC filings. Latest: 8-K (Apr 7, 2026). Includes 14 8-K, 10 SC 13G/A, 6 10-Q.
View Abeona Therapeutics Inc. on SEC EDGAR
Overview
Abeona Therapeutics Inc. (ABEO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Abeona Therapeutics Inc. reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $91.643 million, a stark contrast to the net loss of $54.441 million in the same period of 2024. This improvement was primarily driven by a substantial gain of
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 1 bullish, 35 neutral, 1 mixed. The dominant filing sentiment for Abeona Therapeutics Inc. is neutral.
Filing Type Overview
Abeona Therapeutics Inc. (ABEO) has filed 14 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 10 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of ABEO's 24 recent filings, 0 were flagged as high-risk, 15 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $400,000 |
| Net Income | $91.643M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $82.884M |
| Operating Margin | N/A |
| Total Assets | $231.095M |
| Total Debt | N/A |
Key Executives
- Dr. John F. Crowley
- Dr. John A. McNeish
- Dr. Carsten Brunn
- Ms. Jennifer D. Johnson
- Dr. Carin R. Canter
- Mr. Michael J. Rossi
- Vishwas Seshadri
- James E Flynn
Industry Context
Abeona Therapeutics operates in the highly competitive and rapidly evolving gene therapy and rare disease treatment sector. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Companies often rely on strategic partnerships, licensing agreements, and the sale of valuable regulatory assets like Priority Review Vouchers to fund operations and advance their pipelines.
Top Tags
financials (6) · 10-Q (5) · governance (4) · biotech (3) · material-agreement (3) · pharmaceuticals (3) · sec-filing (3) · 8-k (3) · executive-compensation (3) · Abeona Therapeutics (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $91.643M | for the nine months ended September 30, 2025, a significant turnaround from a $54.441M loss in 2024. |
| Gain from PRV Sale | $152.366M | primary driver of net income for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $82.884M | as of September 30, 2025, up from $23.357M at December 31, 2024. |
| Selling, General and Administrative Expenses | $46.249M | increased 108.6% for the nine months ended September 30, 2025, reflecting commercialization efforts. |
| Research and Development Expenses | $20.100M | decreased 20.7% for the nine months ended September 30, 2025. |
| Total Stockholders' Equity | $171.233M | as of September 30, 2025, up from $44.031M at December 31, 2024. |
| Loss from Operations | $66.537M | for the nine months ended September 30, 2025, indicating ongoing operational burn without the PRV gain. |
| Common Shares Outstanding | 54,191,361 | as of November 7, 2025, indicating potential dilution from prior equity raises. |
| Reporting Period | Q2 2025 | Second quarter financial results |
| Period End Date | 2025-06-30 | End of the reporting quarter |
| Prior Year Quarter End | 2024-06-30 | For comparative analysis |
| Reporting Period End | 20250331 | The end date for the financial data presented in this 10-Q filing. |
| Filing Date | 20250515 | The date this 10-Q report was officially submitted to the SEC. |
| Fiscal Year | 2024 | Reporting period for executive compensation and equity awards. |
| Prior Fiscal Year | 2023 | Used for comparative analysis of compensation and equity awards. |
Forward-Looking Statements
- {"claim":"Deerfield Management will maintain a significant stake in Abeona Therapeutics throughout 2024.","entity":"Deerfield Management Company, L.P.","targetDate":"December 31, 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Abeona Therapeutics Inc. (ABEO)?
Abeona Therapeutics Inc. has 37 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 10 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ABEO filings?
Across 37 filings, the sentiment breakdown is: 1 bullish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Abeona Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Abeona Therapeutics Inc. (ABEO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Abeona Therapeutics Inc.?
Key financial highlights from Abeona Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ABEO?
The investment thesis for ABEO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Abeona Therapeutics Inc.?
Key executives identified across Abeona Therapeutics Inc.'s filings include Dr. John F. Crowley, Dr. John A. McNeish, Dr. Carsten Brunn, Ms. Jennifer D. Johnson, Dr. Carin R. Canter and 3 others.
What are the main risk factors for Abeona Therapeutics Inc. stock?
Of ABEO's 24 assessed filings, 0 were flagged high-risk, 15 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Abeona Therapeutics Inc.?
Recent forward-looking statements from Abeona Therapeutics Inc. include guidance on {"claim":"Deerfield Management will maintain a significant stake in Abeona Therapeutics throughout 2024.","entity":"Deer.